PMID- 35545872
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220925
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 94
IP  - 9
DP  - 2022 Sep
TI  - Efficacy and safety of direct-acting antiviral therapies and baseline predictors 
      for treatment outcomes in hepatitis C patients: A multicenter, real-world study 
      in Guangdong, China.
PG  - 4459-4469
LID - 10.1002/jmv.27851 [doi]
AB  - The data on direct-acting antivirals (DAAs) in chronic hepatitis C (CHC) patients 
      in southern China with multiple genotypes circulating are limited. This study 
      aims to evaluate the efficacy and safety of DAA regimens among CHC patients in 
      Guangdong, China. A total of 220 patients receiving a variety of DAA were 
      enrolled. The primary outcome was sustained virologic response (SVR) at 12 weeks. 
      Resistance associated substitutions (RASs) were evaluated by deep sequencing. The 
      overall SVR rate was 96.4%, and was 97.7% for genotype 1, 100% for genotype 2, 
      91.9% for genotype 3, 95.7% for genotype 6, and 100% for untyped. The overall 
      incidence of adverse events (AEs) was 8.2% (18/220) and all the AEs were mild. 
      Nonstructural proteins 5A RAS, 30K/31M, and Y93H were most prevalent at baseline 
      and the end of treatment in non-SVR patients, respectively. Logistics regression 
      showed that elevated alanine aminotransferase (ALT) and aspartate 
      aminotransferase (AST) at baseline were specifically associated with non-SVR in 
      patients with genotype 3 and 6 infections (p = 0.029 and p = 0.017) but not 
      genotype 1 infection (p = 0.746 and p = 0.971), and baseline AST was the best 
      predictor for SVR in genotypes 3 and 6 patients (area under curve = 0.890). Our 
      studies demonstrated all DAA regimens achieved ideal SVR and were well tolerated. 
      NS5A RAS were prevalent in non-SVR patients. Elevated ALT and AST as baseline 
      predictors for non-SVR in genotypes 3 and 6 infections warrant further research 
      in a larger cohort.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Xie, Zhiwei
AU  - Xie Z
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
FAU - Deng, Kai
AU  - Deng K
AD  - Infectious Disease Institute, Guangzhou Eighth People's Hospital, Guangzhou 
      Medical University, Guangzhou, Guangdong, China.
FAU - Xia, Yang
AU  - Xia Y
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
FAU - Zhang, Chunlan
AU  - Zhang C
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
FAU - Xu, Min
AU  - Xu M
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
FAU - Li, Feng
AU  - Li F
AUID- ORCID: 0000-0002-7690-8870
AD  - Infectious Disease Institute, Guangzhou Eighth People's Hospital, Guangzhou 
      Medical University, Guangzhou, Guangdong, China.
FAU - Liu, Jinfeng
AU  - Liu J
AD  - Institution of Clinical Research, the First People's Hospital of Foshan, Foshan, 
      Guangdong, China.
FAU - Zhou, Yuanping
AU  - Zhou Y
AD  - Department of Infectious Disease, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Chen, Xiaoping
AU  - Chen X
AD  - Department of Infectious Disease, Guangdong Provincial People's Hospital, 
      Guangzhou, China.
FAU - Chen, Xuefu
AU  - Chen X
AD  - Department of Infectious Disease, Guangdong Provincial People's Hospital, 
      Guangzhou, China.
FAU - Yan, Qin
AU  - Yan Q
AD  - Department of Hepatology, Shenzhen Union Hospital of Huazhong University of 
      Science and Technology, Shenzhen, Guangdong, China.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Infectious Disease, Guangdong Provincial People's Hospital, 
      Guangzhou, China.
FAU - Chen, Wenli
AU  - Chen W
AD  - Department of Infectious Disease, Guangdong Provincial People's Hospital, 
      Guangzhou, China.
FAU - Wu, Shuduo
AU  - Wu S
AD  - Department of Hepatology, Guangdong Province Hospital of Traditional Chinese 
      Medicine, Guangzhou, China.
FAU - Bai, Honglian
AU  - Bai H
AD  - Institution of Clinical Research, the First People's Hospital of Foshan, Foshan, 
      Guangdong, China.
FAU - Li, Jianping
AU  - Li J
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
FAU - Guan, Yujuan
AU  - Guan Y
AD  - Department of Hepatology, Guangzhou Eighth People's Hospital, Guangzhou Medical 
      University, Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220531
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Antiviral Agents)
RN  - 0 (Viral Nonstructural Proteins)
SB  - IM
MH  - *Antiviral Agents/adverse effects/therapeutic use
MH  - Drug Resistance, Viral/genetics
MH  - Drug Therapy, Combination
MH  - Hepacivirus/genetics
MH  - *Hepatitis C, Chronic/drug therapy
MH  - Humans
MH  - Sustained Virologic Response
MH  - Treatment Outcome
MH  - Viral Nonstructural Proteins/genetics
OTO - NOTNLM
OT  - AST
OT  - chronic hepatitis C
OT  - genotype 3 and 6
OT  - resistance-associated substitutions
OT  - sustained virologic response
EDAT- 2022/05/13 06:00
MHDA- 2022/07/16 06:00
CRDT- 2022/05/12 03:03
PHST- 2022/04/25 00:00 [revised]
PHST- 2022/01/18 00:00 [received]
PHST- 2022/05/09 00:00 [accepted]
PHST- 2022/05/13 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/05/12 03:03 [entrez]
AID - 10.1002/jmv.27851 [doi]
PST - ppublish
SO  - J Med Virol. 2022 Sep;94(9):4459-4469. doi: 10.1002/jmv.27851. Epub 2022 May 31.